| BE177467 |
315706-13-9 |
4EGI-1 |
|
|
|
| BE177466 |
328998-25-0 |
4E1RCAt |
|
|
|
| BZ177457 |
2098191-53-6 |
Zotatifin |
|
|
|
| BT177456 |
172854-68-1 |
Ternatin 4 |
|
|
|
| BR177455 |
932736-91-9 |
RS-PPCC |
|
|
|
| BP177454 |
1632250-16-8 |
PF 846 |
|
|
|
| BP177453 |
154130-99-1 |
PD 144418 oxalate |
|
|
|
| BP177452 |
172906-90-0 |
PB 28 dihydrochloride |
|
|
|
| BM177451 |
1797406-69-0 |
MZ1 |
|
|
|
| BM177450 |
1346527-98-7 |
ML 240 |
|
|
|
| BE177449 |
878141-96-9 |
E 52862 (S1RA) |
|
|
|
| BD177448 |
1950634-92-0 |
dBET6 |
|
|
|
| BD177447 |
177355-84-9 |
DBeQ |
|
|
|
| BC177446 |
1380087-89-7 |
CPI 0610 |
|
|
|
| BC177445 |
1542705-92-9 |
CB 5083 |
|
|
|
| BY177444 |
195889-55-5 |
YH-1238 |
|
|
|
| BK177443 |
170365-25-0 |
KW 8232 |
|
|
|
| BE177442 |
115464-77-2 |
Elopiprazole |
|
|
|
| BS177441 |
980601-49-0 |
SB 616234-A |
|
|
|
| BA177440 |
1232221-74-7 |
APY0201 |
|
|
|
| BZ177439 |
1216792-30-1 |
ZK 93426 Hydrochloride |
|
|
|
| BS177438 |
115621-95-9 |
SDZ-62-434 |
|
|
|
| BP177437 |
133737-32-3 |
Pagoclone |
|
|
|
| BO177436 |
868273-90-9 |
ONO 5334 |
|
Cathepsin K inhibitor |
|
| BM177435 |
1010731-97-1 |
MLN-3897 |
|
|
|
| BL177434 |
178600-20-9 |
LGD-1550 = ALRT-1550 |
|
|
|
| BG177433 |
148642-42-6 |
GR 127935 hydrochloride hydrate |
|
|
|
| BA177432 |
32571-49-6 |
AQ-13 (2HCl) |
|
|
|
| BA177431 |
870087-36-8 |
Apilimod mesylate |
|
|
|
| BA177430 |
541550-19-0 |
Apilimod |
|
|
|
| BA177429 |
126048-33-7 |
AL 3152 |
|
|
|
| BX174908 |
61970-00-1 |
X-Shining™ Luciferase - 10 mg/mL aqueous solution with glycerol |
|
Recombinant luciferase optimized for increased stability |
|
| BR172011 |
1342278-01-6 |
RKI-1447 |
|
RKI-1447 is a potent inhibitor of ROCK1 and ROCK2, with IC50 of 14.5 nM and 6.2 |
|
| NA171964 |
71494-28-5 |
3-(3-Acetamido-3-carboxypropyl)uridine |
|
acetylated derivative from 3-(3-amino-3-carboxypropyl)uridine |
|
| BW170250 |
2247544-02-9 |
WS 383 hydrochloride |
|
Inhibitor of DCN1−UBC12 interaction |
|
| BE170203 |
55854-43-8 |
ES9-17 |
|
Inhibitor of clathrin-mediated endocytosis |
|
| BW170171 |
1338574-93-8 |
WWL 154 |
|
Inhibitor of fatty acid amide hydrolase FAAH-4 |
|
| BS168651 |
2101958-02-3 |
Squarunkin A |
|
Inhibitor of UNC119-cargo interaction |
|
| BF168573 |
1359963-68-0 |
FEMA 4774 |
|
Agonist of taste receptors T1R2 and T1R3; sweetness enhancer |
|
| BG168557 |
2101315-36-8 |
Gboxin |
|
Inhibitor of oxidative phosphorylation; cytotoxic to glioblastoma |
|
| BB168529 |
342795-08-8 |
Bragsin 2 |
|
Inhibitor of BRAG2-induced activation of Arf GTPase |
|
| BV168436 |
1976050-09-5 |
Valiglurax |
|
Positive allosteric modulator of metabotropic glutamate receptor mGluR4 |
|
| BB168381 |
924537-98-4 |
BT 13 |
|
Inhibitor of RET signalling; GFL mimetic |
|
| BF168364 |
329932-55-0 |
FM 19G11 |
|
Inhibitor of HIF1α transcription factor |
|
| BO168359 |
304478-23-7 |
O151 |
|
Inhibitor of 8-oxoguanine DNA glycosylase OGG1 |
|
| BB168324 |
2227549-00-8 |
BI 01383298 |
|
Inhibits SLC13A5 sodium-citrate co-transporter |
|
| BS168256 |
|
SET2 |
|
Transient receptor potential vanilloid channel TRPV2 inhibitor; anti-metastatic |
|
| BB168136 |
724440-27-1 |
BAY 8002 |
|
Inhibitor of monocarboxylate transporter MCT1; inhibitor of lactate transport |
|
| BT168024 |
2304947-71-3 |
TH 5487 |
|
Inhibitor of OGG1 DNA glycosylase |
|
| BC168017 |
2244579-87-9 |
C2 |
|
Positive allosteric modulator of cannabinoid CB2 receptors |
|